医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures

2014年08月12日 PM11:00
このエントリーをはてなブックマークに追加


 

TOKYO

Tokyo-based Atonarp Inc. announced today $8 million in a Series A funding round led by Walden Riverwood Ventures with participation from other co-investors. The funding accelerates the development of Atonarp’s Smart Spectrometer technology platform, which will enable a broad range of applications. The company has targeted the oil & gas and healthcare industries for its initial products.

“We are excited to partner with Atonarp in pursuing the commercialization of its Smart Spectrometer platform. Atonarp has a unique combination of engineering, semiconductor and data analysis talent and fundamental technologies. These are being used by Atonarp to create disruptive, next generation measurement instruments,” said Nicholas Brathwaite, co-founder of Walden Riverwood Ventures and Chairman of Atonarp, Inc.

Atonarp is pioneering the field of chemical composition analysis by combining state-of-the-art electronics and data processing algorithms. Atonarp’s Smart Spectrometer will enable manufacturers of gas-composition analysis instruments, such as field-based gas chromatography equipment, to achieve breakthrough improvements in cost, size, accuracy and maintenance-free operation without the need for expensive carrier gases. The Smart Spectrometer platform is also enabling novel use cases and applications for manufacturers of medical equipment and patient devices, including non-invasive, highly accurate personal healthcare monitoring.

Atonarp is currently sampling its Smart Spectrometer platform to leading manufacturers of oil & gas and healthcare instruments, and will enter volume production early next year.

About Walden Riverwood Ventures
Walden Riverwood Ventures is a venture capital firm focused on investing in core technology companies globally. It was formed as a collaboration between Walden International, a leading international venture capital firm, and Riverwood Capital, a global, technology-focused private equity firm. The firm’s founding partners provide its portfolio companies with unique access to deep industry knowledge, relationships and management experience. The two firms have an established history of investing together in several successful companies such as GoPro (NASDAQ: GPRO), Ambarella, Inc. (NASDAQ: AMBA), and Aptina Imaging, Inc. Walden Riverwood Ventures leads early stage investments in companies developing fundamental technologies that have the potential to benefit multiple industry verticals. For further information, please visit www.waldenintl.com and www.riverwoodcapital.com.

CONTACT

For more information, please contact:
Walden Riverwood Ventures
Cesar
Lee, +1(650)618-7313
cesar@rwcm.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists